Adjuvant Treatment with Temodar plus Avastin Alone or with Tarceva in Patient with Newly Diagnosed Glioblastoma Multiforme Who Are Stable Following Radiotherapy with Temodar

Sponsor: Genentech, Inc.

Location(s): United States


This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately following a standard course of up-front radiotherapy and Temodar. All patients will receive Bevacizumab, Temodar and Tarceva. A total of 60 patients will be enrolled. Our hypothesis is that the combination of Bevacizumab plus Temodar and Tarceva will increase survival over that seen in historical controls who have newly diagnosed, non-progressive glioblastoma or gliosarcoma following radiotherapy plus Temodar and use Temodar alone.